Tocagen (NASDAQ:TOCA) is scheduled to issue its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.75) per share for the quarter.
Tocagen (NASDAQ:TOCA) last released its earnings results on Tuesday, May 7th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.01. Tocagen had a negative net margin of 294.74% and a negative return on equity of 108.08%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $2.01 million. On average, analysts expect Tocagen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of NASDAQ TOCA traded down $0.21 during midday trading on Tuesday, reaching $4.52. The company’s stock had a trading volume of 3,447 shares, compared to its average volume of 155,781. The company has a current ratio of 5.05, a quick ratio of 5.05 and a debt-to-equity ratio of 0.75. The stock has a 50 day moving average price of $5.85. Tocagen has a one year low of $4.13 and a one year high of $15.80. The stock has a market capitalization of $110.82 million, a P/E ratio of -1.86 and a beta of 3.90.
TOCA has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $14.50 target price on shares of Tocagen in a report on Thursday, May 9th. Chardan Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Tocagen in a report on Wednesday, May 22nd. Citigroup initiated coverage on shares of Tocagen in a report on Thursday, May 30th. They issued a “buy” rating on the stock. ValuEngine upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald initiated coverage on shares of Tocagen in a report on Thursday, April 25th. They issued an “overweight” rating and a $28.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $16.08.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Further Reading: Understanding the different types of bonds
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.